This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I01 (Rheumatic fever with heart involvement) | Special Copayment Reduction: V192 (Special Copayment Reduction for heart disease: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Acute rheumatic carditis, rheumatic endocarditis, rheumatic myocarditis, rheumatic pericarditis, rheumatic pancarditis |
| C. Adult onset | Acute rheumatic fever occurs mainly in children aged 5–15 years, but initial attacks or recurrences are also possible in adults. In adult onset, the rate of carditis is high and valve damage may progress rapidly. |
| 1. History | First described by Sydenham in the 17th century. Association with streptococci established in the 19th century. Diagnosis systematized with the Jones criteria (1944). Incidence fell sharply with antibiotics. |
| 2. Causes | Autoimmune reaction following group A streptococcal (GAS, Group A Streptococcus pyogenes) pharyngitis. Antibody cross-reactivity against the M protein causes cardiac tissue damage. |
| 3. Genetics | Associations with HLA class II genes (HLA-DR7, HLA-DR53, etc.) reported. Polymorphisms in immune-response regulatory genes determine susceptibility. Familial clustering observed. |
| 4. General epidemiology | Approximately 33.9 million people worldwide affected by rheumatic heart disease. Occurs mainly in low- and middle-income countries. Approximately 300,000 deaths per year. Incidence is low in Korea, but caution is needed in immigrants. |
| 5. Pathophysiology | Autoimmune reaction due to molecular similarity between streptococcal M protein epitopes and cardiac proteins (myocardial myosin, valvular endothelium). Characterized by Aschoff body formation. |
| 6. Symptoms | Fever, migratory polyarthritis, carditis (palpitations, dyspnea, chest pain), skin nodules, erythema marginatum, Sydenham's chorea. |
| 7. Signs | Three cardinal signs of carditis: new heart murmur, pericardial friction rub, cardiomegaly. Carey-Coombs murmur (mitral flow murmur), subcutaneous nodules, erythema marginatum. |
| 8. Screening | Throat culture, ASO titer measurement. Handheld echocardiography recommended for screening children in high-risk regions for asymptomatic rheumatic heart disease (WHO 2024). |
| 9. Diagnosis | Revised Jones criteria (2015 AHA): includes 5 major criteria and minor criteria. Confirmation of carditis by echocardiography is superior to clinical murmur. Evidence of streptococcal infection is required. |
| 10. Treatment | Primary: eradication of streptococci with intramuscular benzathine penicillin G. Anti-inflammatory: aspirin, naproxen (arthritis), corticosteroids (severe carditis). Rest and diuretics as adjuncts. |
| 11. Prognosis | Severity of carditis and number of recurrences are the determinants of valve damage. Approximately 50–70% of initial carditis progresses to chronic rheumatic heart disease. Secondary prophylaxis is key. |
| 12. Prevention | Primary prevention: appropriate antibiotic treatment of streptococcal pharyngitis (penicillin for 10 days). Secondary prevention: regular administration of benzathine penicillin G (with carditis, at least 10 years or until age 40). |
| 13. References | Acute rheumatic fever and rheumatic heart disease: updates in diagnosis and treatment … and 9 other papers |
The history of rheumatic fever begins with the 17th-century English physician Thomas Sydenham (1624–1689), who first systematically described 'a febrile illness with migratory joint pain and cardiac involvement.' He called the disease 'febris rheumatica' at the time and presented migratory arthritis as its key clinical feature. Sydenham also described an involuntary movement syndrome associated with this disease, which was later named 'Sydenham's chorea.'
In the 19th century, the pathological understanding of rheumatic fever advanced. In 1835, Jean-Baptiste Bouillaud of France systematically studied the association between rheumatic fever and endocarditis, confirming that cardiac involvement is a key complication of the disease. In 1904, the German pathologist Ludwig Aschoff described the 'Aschoff body,' the characteristic pathological finding of rheumatic myocarditis, establishing histological diagnostic criteria for rheumatic carditis. This tissue finding is still used today as the basis for pathological confirmation of rheumatic myocarditis.
In the early 20th century, the causal relationship between streptococcal pharyngitis and rheumatic fever began to be established. Studies conducted in U.S. military barracks in the 1940s (Jones, Coburn, and others) epidemiologically demonstrated that group A beta-hemolytic Streptococcus infection is the antecedent event of rheumatic fever. In 1944, T. Duckett Jones published the 'Jones Criteria' to systematize clinical diagnosis, and these criteria have since been revised several times, most recently by the American Heart Association (AHA) in 2015.
The arrival of the antibiotic era dramatically changed the epidemiology of rheumatic fever. After the clinical introduction of penicillin in the 1940s, the incidence of rheumatic fever and the resulting prevalence of rheumatic heart disease fell sharply in developed countries. However, in low- and middle-income countries, streptococcal infections are still not adequately treated, so the burden of rheumatic fever and rheumatic heart disease remains high. The latest guideline published by WHO in 2024 recommends screening for asymptomatic rheumatic heart disease using handheld echocardiography in high-risk regions and emphasizes strengthening secondary prophylaxis programs.
The direct cause of rheumatic fever with heart involvement is pharyngeal infection with group A beta-hemolytic Streptococcus (Group A Streptococcus, GAS, Streptococcus pyogenes). Skin infection (impetigo) does not cause rheumatic fever; only pharyngeal and tonsillar infections are recognized as antecedent events. Rheumatic fever develops after a latent period of about 2–4 weeks following GAS infection, and progression to rheumatic fever is blocked if appropriate antibiotic treatment is received.
The M protein of GAS is the key virulence factor. Certain epitopes of the M protein (especially types M1, M3, M5, M18, and M24) share structural similarity with cardiac proteins (the S2 fragment of myocardial myosin, vimentin and laminin of the valvular endothelium, etc.), inducing an autoimmune reaction by the mechanism of molecular mimicry. Antibodies produced in this reaction and activated T cells attack cardiac tissue.
Not all patients infected with GAS progress to rheumatic fever. Only about 1–3% of patients with untreated GAS pharyngitis develop rheumatic fever. This means that host genetic susceptibility, characteristics of the immune response, and the rheumatogenicity of the organism act in combination. Because the frequency and severity of carditis increase with recurrence of rheumatic fever, secondary prophylaxis is absolutely important.
Genetic factors play an important role in individual susceptibility to rheumatic fever and rheumatic heart disease. The most consistently reported genetic association is with HLA (human leukocyte antigen) class II genes. Alleles such as HLA-DR7, HLA-DR53, and HLA-DQ1 have been reported to be associated with increased susceptibility to rheumatic fever in certain ethnic groups.
In addition to HLA, studies have been published showing that polymorphisms of cytokine genes such as TNF-α, IL-1, and IL-6 are associated with the onset of rheumatic fever and the severity of carditis. Polymorphisms of Fc receptor genes (FCGR2A, FCGR3A) are also presumed to be involved in antibody-mediated cardiac damage. Variants in genes related to T-cell costimulatory molecules such as CD40L and CTLA-4 have also been reported.
In familial aggregation studies, the risk of disease in siblings of rheumatic fever patients is significantly higher than in the general population, confirming the importance of genetic predisposition. However, the fact that concordance in monozygotic twin studies does not reach 100% suggests that environmental factors (GAS exposure, hygiene, crowded environments, etc.) also act together. To date, no single gene variant causing rheumatic fever has been identified, and it is understood to follow complex polygenic inheritance.
Rheumatic heart disease (RHD) affects approximately 33.9 million people worldwide and is estimated to cause about 300,000 deaths per year (GBD 2019). Acute rheumatic fever occurs mainly in children and adolescents aged 5–15 years and is rare under age 5 or over age 25. However, initial attacks or recurrences in adults have also been reported.
Geographic distribution is extremely uneven. Prevalence is highest in low- and middle-income countries (sub-Saharan Africa, South Asia, Oceania, parts of South America), because environmental factors such as household crowding, poor hygiene, and lack of access to health care lead to transmission of GAS infection and delayed treatment. In developed countries, incidence has decreased markedly since the 1940s owing to the spread of antibiotics and improved living conditions.
In developed East Asian countries, including Korea, the incidence of rheumatic fever is very low, but cases are not absent. In particular, undiagnosed rheumatic heart disease may be found in immigrants or international students from high-prevalence regions such as Africa and South Asia, so caution is needed. Approximately 470,000 new cases of acute rheumatic fever are estimated to occur worldwide each year, and the cumulative burden of the resulting rheumatic heart disease remains enormous.
The key pathophysiology of cardiac involvement in rheumatic fever is an autoimmune reaction by molecular mimicry. The M protein and N-acetyl-β-D-glucosamine (GlcNAc) of group A Streptococcus share structural epitope similarity with the S2 fragment of cardiac myosin and with vimentin, laminin, tropomyosin, and others on the surface of valvular endothelial cells. Cross-reactive antibodies generated against these and autoreactive CD4⁺ T cells infiltrate cardiac tissue and cause inflammation.
Pathologically, in the acute phase, pancarditis occurs, involving all three layers of the heart (endocardium, myocardium, pericardium). Myocarditis forms characteristic granulomatous lesions called Aschoff bodies, structures in which a central necrotic area is surrounded by Aschoff cells (activated macrophages) and lymphocytes. Endocarditis forms small verrucous thrombi along the valve closure line, and with repeated recurrences of rheumatic fever these progress to fibrosis, adhesion, and calcification, becoming fixed as chronic valvular disease.
Pericarditis appears in the form of 'bread and butter pericarditis,' in which fibrinous exudate accumulates between the visceral and parietal pericardium. Pericarditis causes chest pain and friction rub in the acute phase, but progression to chronic constrictive pericarditis is rare. The most important determinant of valve damage is the number of recurrences; as recurrences repeat, fibrosis and calcification accumulate and stenosis and regurgitation worsen.
The clinical symptoms of acute rheumatic fever with heart involvement appear suddenly after an asymptomatic period of 2–4 weeks following the antecedent infection (pharyngitis). Migratory polyarthritis is the most common major manifestation; it characteristically involves large joints (knees, ankles, elbows, wrists) in succession, resolving in the affected joint within a few days and moving to another joint.
Carditis occurs in 50–80% of patients with acute rheumatic fever, and is clinically apparent in about 50% of these. Palpitations, dyspnea, chest pain (with pericarditis), and fatigue are the main symptoms. In severe carditis, acute heart failure (pulmonary edema, orthopnea) may occur, resulting from a combination of valvular regurgitation and myocardial dysfunction.
Sydenham's chorea is characterized by involuntary movements and emotional lability and is observed in 10–30% of patients with acute rheumatic fever. It may appear several months after pharyngitis, so the association with the preceding infection may be missed. Subcutaneous nodules are painless, firm nodules mainly over bony prominences, and erythema marginatum is a red ring-shaped rash on the trunk and proximal limbs, characteristically with a clear center and only the margins red.
The three cardinal signs of cardiac involvement are the appearance of a new heart murmur, a pericardial friction rub, and cardiomegaly. A new heart murmur is due to acute regurgitation of the mitral or aortic valve, and the mitral regurgitation murmur (apical pansystolic murmur) is the most common. The Carey-Coombs murmur is a short, low-pitched murmur heard in early diastole, caused by increased flow across the mitral valve and mild stenosis, and is a characteristic sign of acute carditis.
A pericardial friction rub is heard when pericarditis is present, during both inspiration and expiration, and is better heard with the patient leaning forward. Cardiomegaly is confirmed on echocardiography as enlargement of the left ventricle or the whole heart and appears with severe myocarditis or moderate or greater valvular regurgitation. A murmur unrelated to change in position, tachycardia (heart rate >100/min), and PR interval prolongation on ECG (first-degree atrioventricular block) are also among the minor criteria of carditis.
When arthritis is present, redness, warmth, swelling, and tenderness of the affected joints are prominent; in Sydenham's chorea, physical findings such as irregular involuntary movements of the face and limbs, hypotonia, and milkmaid's grip are seen. Subcutaneous nodules are painless, hard, mobile nodules over tendon insertions, palpated on the scalp, elbows, fingers, heels, and elsewhere.
Screening strategies for acute rheumatic fever and rheumatic heart disease are divided into primary prevention (early diagnosis and treatment of streptococcal infection) and early detection of asymptomatic rheumatic heart disease (screening for secondary prophylaxis). In patients with sore throat, confirming GAS infection with a rapid antigen detection test (RADT) or throat culture is the key to primary prevention.
In regions at risk for rheumatic fever (high-prevalence regions), echocardiographic screening programs for school-age children are recommended. The WHO 2024 guideline presents evidence that handheld echocardiography is markedly superior to traditional auscultation-based screening in detecting asymptomatic rheumatic heart disease, and recommends it as the primary screening tool. Rheumatic heart disease detected only on echocardiography without clinical findings (latent RHD) is also a target for secondary prophylaxis.
For serologic testing, the titer of the anti-streptococcal antibody ASO (antistreptolysin-O) is the standard test and is elevated in about 80% of patients with rheumatic fever. A significant rise in titer measured 2–4 weeks apart is more meaningful than a high ASO titer at a single time point. Adding other anti-streptococcal antibody tests such as anti-DNase B, antihyaluronidase, and antistreptokinase can increase the sensitivity for evidence of streptococcal infection.
Diagnosis of acute rheumatic fever follows the clinical criteria of the revised Jones criteria (2015 AHA revision). The applicable criteria differ by risk group (low risk vs. moderate/high risk), and the diagnosis is made when, together with evidence of streptococcal infection, two or more major criteria, or one major criterion plus two or more minor criteria, are met.
The major criteria are ① carditis (clinical or subclinical echocardiographic findings), ② migratory polyarthritis, ③ Sydenham's chorea, ④ erythema marginatum, and ⑤ subcutaneous nodules. In high-risk populations, monoarthritis or polyarthralgia may also be included in the major criteria. The minor criteria are fever, prolonged PR interval, elevated CRP or ESR, and arthralgia (when not included in the major criteria).
Echocardiography is essential for diagnosing subclinical carditis in which no murmur is clinically audible, and the 2015 revised Jones criteria were changed so that echocardiographic findings alone can satisfy the major criterion of carditis. Findings assessed on echocardiography include mitral regurgitation, aortic regurgitation, pericardial effusion, and thickening or abnormal motion of the valve leaflets. Evidence of streptococcal infection (positive throat culture, positive RADT, or elevated ASO/anti-DNase B) is a required condition for diagnosis.
The first step of treatment is complete eradication of GAS infection. A single intramuscular injection of benzathine penicillin G (BPG) 1.2 million units (0.6 million units for body weight 27 kg or less) or a 10-day course of oral penicillin V is standard. In case of penicillin allergy, amoxicillin, cephalosporins, or macrolide antibiotics are used.
For anti-inflammatory treatment, aspirin (75–100 mg/kg/day, maximum 4–6 g/day) or naproxen is effective for arthritis, tapered gradually after symptoms improve. In severe carditis (cardiomegaly, heart failure, grade III or higher valvular regurgitation), corticosteroids (prednisone 1–2 mg/kg/day, maximum 80 mg/day, tapered after 2–3 weeks) are used. However, to date there is no evidence that anti-inflammatory treatment prevents progression to chronic rheumatic heart disease.
When heart failure is present, heart failure treatment such as diuretics, ACE inhibitors, and angiotensin receptor blockers is given concurrently. Bed rest is recommended in the severe stage of acute carditis as part of supportive therapy to reduce cardiac workload and prevent worsening of inflammation. In Sydenham's chorea, anticonvulsants (valproic acid, carbamazepine) or neuroleptics (haloperidol) are used for symptom relief.
The prognosis of acute rheumatic fever is determined by the presence and severity of cardiac involvement. Without carditis, the prognosis is good, and arthritis and chorea resolve completely. With carditis, about 50–70% progress to chronic rheumatic heart disease, which appears mainly as mitral stenosis or regurgitation. In mild carditis at the first episode, spontaneous recovery has been reported in about one-third.
Recurrence is the most important risk factor for worsening of rheumatic heart disease. Without secondary prophylaxis, the risk of recurrence upon exposure to GAS infection is very high, and with each recurrence valve damage accumulates, eventually progressing to severe valvular disease requiring surgical treatment. Adherence to secondary prophylaxis significantly reduces the risk of progression of rheumatic heart disease. Heart failure, stroke, and infective endocarditis are the major complications.
Primary prophylaxis means diagnosing GAS pharyngitis early and preventing the development of rheumatic fever through adequate antibiotic treatment. A 10-day course of oral penicillin V or amoxicillin is standard, and a single intramuscular injection of benzathine penicillin G is equally effective. Starting antibiotics within 9 days of the onset of streptococcal pharyngitis symptoms is very effective in preventing rheumatic fever.
Secondary prophylaxis is the continuous long-term administration of antibiotics to prevent GAS reinfection in patients who have already had rheumatic fever or who have rheumatic heart disease. Intramuscular injection of benzathine penicillin G 1.2 million units every 3–4 weeks is standard. Duration is determined by the presence of carditis and the extent of cardiac involvement; with carditis, at least 10 years or until age 40 (whichever is longer), and lifelong administration is considered when residual valve lesions are present. In case of penicillin intolerance, oral sulfadiazine or erythromycin is an alternative.
Gewitz MH, Baltimore RS, Tani LY, et al. Revision of the Jones Criteria for the diagnosis of acute rheumatic fever in the era of Doppler echocardiography: a scientific statement from the American Heart Association. Circulation. 2015;131(20):1806-1818. DOI: 10.1161/CIR.0000000000000205. PMID: 25908771.
Carapetis JR, Beaton A, Cunningham MW, et al. Acute rheumatic fever and rheumatic heart disease. Nature Reviews Disease Primers. 2016;2:15084. DOI: 10.1038/nrdp.2015.84. PMID: 27188830.
RHD Action. WHO guideline on the prevention and diagnosis of rheumatic fever and rheumatic heart disease. WHO Technical Report. 2024. Available: WHO Publications.
Watkins DA, Johnson CO, Colquhoun SM, et al. Global, regional, and national burden of rheumatic heart disease, 1990–2015. New England Journal of Medicine. 2017;377(8):713-722. DOI: 10.1056/NEJMoa1603693. PMID: 28813214.
Cunningham MW. Pathogenesis of group A streptococcal infections. Clinical Microbiology Reviews. 2000;13(3):470-511. DOI: 10.1128/CMR.13.3.470. PMID: 10885988.
Remenyi B, Wilson N, Steer A, et al. World Heart Federation criteria for echocardiographic diagnosis of rheumatic heart disease—an evidence-based guideline. Nature Reviews Cardiology. 2012;9(5):297-309. DOI: 10.1038/nrcardio.2012.7. PMID: 22371105.
Moons P, Engelfriet P, Kaemmerer H, et al. Prevalence and clinical significance of gout in adults with congenital heart disease. Heart. 2010;96(21):1705-1708. DOI: 10.1136/hrt.2010.196907. PMID: 20943665.
Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet. 2012;379(9819):953-964. DOI: 10.1016/S0140-6736(11)61171-9. PMID: 22405798.
Steer AC, Carapetis JR. Prevention and treatment of rheumatic heart disease in the developing world. Nature Reviews Cardiology. 2009;6(11):689-698. DOI: 10.1038/nrcardio.2009.162. PMID: 19806148.
Essop MR, Nkomo VT. Rheumatic and nonrheumatic valvular heart disease: epidemiology, management, and prevention in Africa. Circulation. 2005;112(23):3584-3591. DOI: 10.1161/CIRCULATIONAHA.105.539197. PMID: 16330697.